Navigation Links
Apexigen Announces the Filing of an IND by its Partner, 3SBio
Date:8/15/2012

BURLINGAME, Calif., Aug. 15, 2012 /PRNewswire/ -- Apexigen, Inc., an emerging biopharmaceutical company focused on the discovery and development of monoclonal antibody therapeutics, announced today that its partner, 3SBio [SSRX] of Shenyang, China, filed an Investigational New Drug (IND) application for APX001, also known as SSS07, with the State Food and Drug Administration (SFDA) in China. Upon approval of the IND, APX001/SSS07 will be studied in clinical trials for the treatment of autoimmune and inflammatory diseases. APX001/SSS07 was discovered through the use of Apexigen's proprietary monoclonal antibody technologies and has been developed by 3SBio in China under a license from Apexigen. APX001/SSS07 is the second antibody discovered through the use of Apexigen's technologies for which an IND has been filed with the SFDA.

"We congratulate our colleagues at 3SBio on this IND filing," said Dr. Xiaodong Yang, President and CEO of Apexigen. "It represents the hard work of many individuals working collaboratively as a team to achieve the common goal. We look forward to continuing success in our collaboration."

About Apexigen, Inc.

Apexigen, Inc. is an emerging biopharmaceutical company focused on improving patient care by translating the unique attributes of its proprietary antibody technologies into superior therapeutics for the treatment of cancer and other difficult-to-treat diseases.  Apexigen has a robust antibody platform technology and a pipeline of seven humanized antibody product candidates.  Apexigen's proprietary antibody technologies produce a broad diversity of antibodies with high specificity and high affinity against unique epitopes.  It can successfully generate antibodies against challenging antigens where competing technologies fail.  This technology allows Apexigen to identify antibodies with unique functional characteristics for optimal therapeutic benefit.

Developing its product pipeline
'/>"/>

SOURCE Apexigen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
(Date:7/10/2014)... CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of $0.275 (27.5 cents) per share on the ... 2014, to holders of record on July 21, 2014. ... dedicated to helping people on their path to better health ... United States . Through the company,s more than 7,600 ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... AlloSource, one of the nation,s largest non-profit providers of ... procedures and the world,s largest processor of live cellular bone ... judged by the ColoradoBiz Top Company awards program. ... for the past decade, AlloSource saved and enhanced the lives ...
... Health Organization has issued a warning to medical travelers: ... heels of a growing threat of an antibiotic-resistant superbug, ... the region in India where it was discovered. "Many ... or knee replacements, ACL surgeries, root canals and spinal ...
Cached Medicine Technology:AlloSource Named Colorado's Top Healthcare Company 2New York Plastic Surgery News: Medical Tourists Beware of Drug-Resistant Superbug NDM-1 2
(Date:7/10/2014)... New York, US (PRWEB) July 10, 2014 ... . , Merrill DataSite recently streamed the live webinar ... featuring a discussion from a group of several M&A ... are seeing in the broader energy transaction marketplace. These ... hot and how the deal market in this sector ...
(Date:7/10/2014)... A Forever Recovery , an ... off to a great start and gives them a ... launched a new Eating Disorders section of its website ... , Different types of eating disorders ... Disorders (DSM-IV), including anorexia nervosa, bulimia nervosa, and EDNOS ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Men who have a ... cancer, a new study suggests. But the risk ... not involved with the study said more research is ... accurate. For the study, Harvard researchers analyzed data ... for 24 years, starting in 1986. During that time, ...
(Date:7/10/2014)... aggression, who research issues ranging from child abuse to ... of the International Society for Research on Aggression (ISRA) ... State University is hosting the prestigious world meeting, which ... "We are excited to be bringing together leading scholars ... produce fresh ideas about the causes, consequences and solutions ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3
... Mothers who are depressed respond differently to their crying ... according to brain scans at the University of Oregon, ... in non-depressed moms. An infant crying is normal, ... says Jennifer C. Ablow, professor of psychology. For years, ...
... This release is available in Spanish . ... and cooperators have confirmed what many pollen-sensitive people already suspected: ... longer and ends later. Ragweed pollen in some ... almost a month longer than it did in 1995, and ...
... , TUESDAY, Feb. 22 (HealthDay News) -- Despite suggestions ... skin condition known as atopic eczema, a new British ... to relieve sufferers. "Although the outcome is disappointing ... eczema, the outcome of the trial is very clear," ...
... HealthDay Reporter , TUESDAY, Feb. 22 (HealthDay News) -- ... increased risk of ischemic stroke, which typically occurs when blood ... fatty deposits within blood vessels, a new Danish study contends. ... pronounced for triglyceride fats than it is for cholesterol, even ...
... researcher believes there could be a new drug compound ... also help with controlling cholesterol. Salman Hyder, the ... biomedical sciences in the College of Veterinary Medicine and ... discovered that a small molecule, Ro 48-8071, initially developed ...
... leap forward in understanding Huntington,s disease may give patients ... cells and post-mortem brain tissue of Huntington,s disease patients ... that causes brain nerve cells to die. Toning down ... the chain reaction and kept those cells alive, according ...
Cached Medicine News:Health News:Crying baby draws blunted response in depressed mom's brain 2Health News:Crying baby draws blunted response in depressed mom's brain 3Health News:USDA study confirms links between longer ragweed season and climate change 2Health News:Softening Water Does Not Seem to Ease Eczema 2Health News:High Triglyceride Levels Linked to Increased Stroke Risk: Study 2Health News:High Triglyceride Levels Linked to Increased Stroke Risk: Study 3Health News:Compound used to block cholesterol could also kill breast cancer, MU researcher finds 2Health News:Huntington's disease breakthrough equals hope for patients 2
... interoperative placement to stent the ... and continent urinary diversions. Supplied ... for one-time use. CAUTION: Periodic ... not remain indwelling more than ...
... a device that provides effective cutting and simultaneous ... to provide the urologist with the same touch ... the approximate speed and the same ease of ... but with a 45% greater zone of ...
Used for stone manipulation and removal in the renal pelvis under direct vision. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stone manipulation and removal in the renal pelvis under direct vision. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: